Document 0641
 DOCN  M9650641
 TI    Altered in vitro handling of Mycobacterium avium complex by monocytes
       and serum from HIV(+) patients.
 DT    9605
 AU    Swartz RP; Roecklein JA; Pierce PF Jr; Yeager H Jr; Department of
       Medicine, Georgetown University Medical Center,; Washington, DC 20007,
       USA.
 SO    Immunol Invest. 1995 Nov;24(6):987-98. Unique Identifier : AIDSLINE
       MED/96153662
 AB    In patients with acquired immunodeficiency syndrome (AIDS),
       mycobacterial diseases are leading opportunistic infections. The reasons
       for the peculiar propensity for disseminated infection with
       Mycobacterium avium complex (MAC) remain unclear. We have previously
       examined, in detail, the ability of monocytes from healthy donors to
       take up and kill MAC under both nonopsonic and opsonic conditions. We
       have now evaluated the in vitro ability of peripheral blood monocytes
       from HIV(+) patients to take up and kill MAC organisms, and have
       discovered a reduced ability under both nonopsonic and opsonic
       conditions. This reduction is due to: 1) apparent defect(s) in the
       phagocytes themselves, and 2) substance(s) in the HIV(+) serum which
       actively suppresses phagocyte activity.
 DE    Adult  *Blood Bactericidal Activity/DRUG EFFECTS  Cells, Cultured
       Female  Glucans/PHARMACOLOGY  Human  HIV Seronegativity  HIV
       Seropositivity/*BLOOD/*MICROBIOLOGY  Male  Middle Age
       Monocytes/*MICROBIOLOGY/VIROLOGY  Mycobacterium avium
       Complex/*IMMUNOLOGY  Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).